January 24, 2020 -- Evotec and Indivumed announced on January 23 a partnership to collaborate on drug discovery and development of novel therapies for non-small cell lung cancer. The goal of the collaboration is to provide highly effective precision medicine treatments for patients.
Evotec will bring its proprietary bioinformatics analysis platform called PanHunter to the table and also several small-molecule and antibody discovery platforms. Indivumed will provide access to its multiomics cancer database, IndivuType, along with advanced analytics and artificial intelligence capabilities. High-quality oncology patient data will complement advanced multiomics data analysis for the development of small-molecule and antibody therapies.
This agreement is a continuation of a previous joint drug discovery program focused on colorectal cancer started in April 2019.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
